OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials
Dulanji Kuruppu, James North, Amy J. Kovacik, et al.
Advances in Therapy (2021) Vol. 38, Iss. 3, pp. 1614-1626
Open Access | Times Cited: 15
Dulanji Kuruppu, James North, Amy J. Kovacik, et al.
Advances in Therapy (2021) Vol. 38, Iss. 3, pp. 1614-1626
Open Access | Times Cited: 15
Showing 15 citing articles:
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
Simona Sacco, Faisal Mohammad Amin, Messoud Ashina, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 247
Simona Sacco, Faisal Mohammad Amin, Messoud Ashina, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 247
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
Fabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 57
Fabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 57
Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy : The multicenter prospective cohort GARLIT study
Fabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
European Journal of Neurology (2022) Vol. 30, Iss. 1, pp. 224-234
Open Access | Times Cited: 39
Fabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
European Journal of Neurology (2022) Vol. 30, Iss. 1, pp. 224-234
Open Access | Times Cited: 39
Evidence-based guidelines for the pharmacological treatment of migraine
Raffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, et al.
Cephalalgia (2025) Vol. 45, Iss. 4
Closed Access
Raffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, et al.
Cephalalgia (2025) Vol. 45, Iss. 4
Closed Access
Hellenic Headache Society Recommendations for the Use of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide Pathway for the Prevention of Migraine and Cluster Headache—2023 Update
Dimos D. Mitsikostas, A. Alexoudi, Chrysa Arvaniti, et al.
SN Comprehensive Clinical Medicine (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 9
Dimos D. Mitsikostas, A. Alexoudi, Chrysa Arvaniti, et al.
SN Comprehensive Clinical Medicine (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 9
Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population
Simona Guerzoni, Carlo Baraldi, Flavia Lo Castro, et al.
Brain and Behavior (2023) Vol. 13, Iss. 6
Open Access | Times Cited: 9
Simona Guerzoni, Carlo Baraldi, Flavia Lo Castro, et al.
Brain and Behavior (2023) Vol. 13, Iss. 6
Open Access | Times Cited: 9
Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients
Marina de Tommaso, Marianna La Rocca, Silvia Giovanna Quitadamo, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Marina de Tommaso, Marianna La Rocca, Silvia Giovanna Quitadamo, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Updated Canadian Headache Society Migraine Prevention Guideline with Systematic Review and Meta-analysis
Ioana Medrea, Paul E. Cooper, M. J. S. Langman, et al.
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (2024), pp. 1-23
Open Access | Times Cited: 2
Ioana Medrea, Paul E. Cooper, M. J. S. Langman, et al.
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (2024), pp. 1-23
Open Access | Times Cited: 2
The ultimate guide to the anti-CGRP monoclonal antibodies galaxy
Davide Mascarella, Eleonora Matteo, Valentina Favoni, et al.
Neurological Sciences (2022) Vol. 43, Iss. 9, pp. 5673-5685
Closed Access | Times Cited: 8
Davide Mascarella, Eleonora Matteo, Valentina Favoni, et al.
Neurological Sciences (2022) Vol. 43, Iss. 9, pp. 5673-5685
Closed Access | Times Cited: 8
Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study
Takao Takeshima, Hikaru Doi, Satomi Ooba, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 3, pp. 697-714
Open Access | Times Cited: 1
Takao Takeshima, Hikaru Doi, Satomi Ooba, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 3, pp. 697-714
Open Access | Times Cited: 1
The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events
Abimael González‐Hernández, Bruno A. Marichal‐Cancino, Carlos M. Villalón
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 10, pp. 1223-1235
Closed Access | Times Cited: 4
Abimael González‐Hernández, Bruno A. Marichal‐Cancino, Carlos M. Villalón
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 10, pp. 1223-1235
Closed Access | Times Cited: 4
Developments in targeting calcitonin gene-related peptide
Sawsan Alabbad, Nathalia Figueredo, Hsiangkuo Yuan, et al.
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 5, pp. 477-485
Closed Access
Sawsan Alabbad, Nathalia Figueredo, Hsiangkuo Yuan, et al.
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 5, pp. 477-485
Closed Access
(CGRP) Monocloncal antibodies
Claudia Altamura, Luigi Francesco Iannone, Luisa Fofi, et al.
Elsevier eBooks (2024), pp. 363-394
Closed Access
Claudia Altamura, Luigi Francesco Iannone, Luisa Fofi, et al.
Elsevier eBooks (2024), pp. 363-394
Closed Access
Anticuerpos monoclonales anti-PRGC y modificación de la historia natural de la migraña
Mariano Huerta Villanueva, Sergio Campoy Díaz, Albert Muñoz‐Vendrell
Kranion (2022) Vol. 17, Iss. 4
Open Access
Mariano Huerta Villanueva, Sergio Campoy Díaz, Albert Muñoz‐Vendrell
Kranion (2022) Vol. 17, Iss. 4
Open Access
Discontinuing Monoclonal Antibodies Targeting CGRP Pathway After One-Year Treatment: An Observational Longitudinal Cohort Study
Fabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, et al.
Research Square (Research Square) (2021)
Open Access
Fabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, et al.
Research Square (Research Square) (2021)
Open Access
